Jump to main content
Jump to site search

All chapters
Previous chapter Next chapter

CHAPTER 4

Targeting DNA Methylation

The approval of DNA methylation inhibitors azacytidine and decitabine for the treatment of myelodysplastic syndromes and acute myeloid leukaemia has demonstrated that modulation of relatively broad epigenetic regulatory processes can show beneficial efficacy/safety profiles in defined patient groups. This chapter will focus on the biochemical mechanisms controlling DNA methylation, consequences of aberrant DNA methylation in complex chronic diseases, existing modulators of DNA methylation used in the clinic, and opportunities for new drugs targeting this central epigenetic mechanism.

Print publication date: 20 Nov 2015
Copyright year: 2016
Print ISBN: 978-1-84973-882-8
PDF eISBN: 978-1-78262-848-4
ePub eISBN: 978-1-78262-772-2
Citation:
From the book series:
Drug Discovery